Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | GRM5 | P41594 | 3/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | VNN1 | O95497 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909188 | 1.00 | GAA (0.63) | GAAHPGDGRM5CA12CA1 | |
| SCHEMBL5909226 | 1.00 | GAA (0.63) | GAAHPGDGRM5CA12CA1 | |
| SCHEMBL5909260 | 0.84 | HPGD (0.61) | GAAHPGDGRM5CA12CA1 | |
| SCHEMBL5909301 | 0.84 | GAA (0.61) | GAAHPGDGRM5CA12CA1 | |
| SCHEMBL5909277 | 0.83 | ALDH1A1 (0.60) | CA2CNR1CNR2ALDH1A1LMNA | |
| SCHEMBL6275232 | 0.83 | ALDH1A1 (0.60) | CA2CNR1CNR2ALDH1A1LMNA | |
| SCHEMBL5909256 | 0.83 | HPGD (0.56) | GAAHPGDGRM5CA12CA1 | |
| SCHEMBL5909273 | 0.82 | HPGD (0.62) | GAAHPGDGRM5CA12CA1 | |
| SCHEMBL5909303 | 0.82 | GAA (0.58) | GAAHPGDGRM5CA12CA1 | |
| SCHEMBL5909255 | 0.82 | VNN1 (0.52) | GRM5CNR1CNR2GABRA5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | claimed |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| EP-1494672-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| WO-2003086398-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | GAA 1798/4885HPGD 261/4885GRM5 3409/4885 |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | GAA 1798/4885HPGD 261/4885GRM5 3409/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | GAA 1379/4885HPGD 190/4885GRM5 2486/4885 |
| US-20030195192-A1 | Nicotinamides having antiangiogenic activity | NAMPT, NNT, SIRT1 | GAA 1205/4885HPGD 45/4885GRM5 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.